Nan Geng¹, Wenxia Hu¹, Zhikun Liu², Jingwei Su², Wenyu Sun³, Shaonan Xie⁴, Cuimin Ding^1,*

Oncologie, Vol.22, No.4, pp. 245-254, 2020, DOI:10.32604/oncologie.2020.014125

Abstract Objective: This study was set out to inquire into the expression and clinical significance of lncRNA activated by transforming growth factor β (LncRNA-ATB) and in cancer tissues of patients with non-small cell lung cancer (NSCLC). Methods: LncRNA-ATB in cancer tissues and adjacent tissues of 89 NSCLC patients was detected by quantitative real-time polymerase chain reaction (qRT-PCR), and its clinical diagnostic value in NSCLC was determined by receiver operating characteristic (ROC) curves. Based on the median expression of LncRNAATB in NSCLC tissues, 89 patients were allocated into high- and low-expression groups. The 3-year survival rate was… More >

Mehmet Sitki Copur^*†, Julie Marie Wurdeman^†, Debra Nelson^*, Ryan Ramaekers^*, Dron Gauchan^*, David Crockett^*

Oncology Research, Vol.26, No.3, pp. 515-518, 2018, DOI:10.3727/096504017X15128550060375

Abstract Solid tumors involving glandular organs express mucin glycoprotein that is eventually shed into the circulation. As a result, these proteins can easily be measured in the serum and be used as potential tumor markers. The most commonly used tumor markers for breast cancer are CA27-29 and CA15-3, which both measure the glycoprotein product of the mucin-1 (MUC1) gene. CA27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in breast cancer patients. Most oncology clinical practice guidelines do not recommend the use of tumor markers for routine surveillance of early… More >

Robert K. Nam¹, Ants Toi², Laurence H. Klotz¹, John Trachtenberg³, Michael A. S. Jewett³, Andrew Loblaw⁴, Greg R. Pond¹, Marjan Emami¹, Linda Sugar⁵, Joan Sweet⁶, Steven A. Narod⁷

Canadian Journal of Urology, Vol.13, Suppl.2, pp. 2-10, 2006

Abstract Background: There is a large amount of confusion in interpreting prostate specific antigen (PSA) values for prostate cancer. More precise risk assessments for prostate cancer detection are needed for men faced with an abnormal PSA.
Methods: We studied a sample of 2637 men who underwent a prostate biopsy for an abnormal digital rectal exam (DRE) or PSA. Using factors including age, ethnicity, family history of prostate cancer, previous negative biopsy, presence of voiding symptoms, prostate volume, DRE and PSA, we constructed nomograms to predict the probability of prostate cancer at biopsy.
Results: Of the 2637 men, 1282 men… More >

Yves Fradet

Canadian Journal of Urology, Vol.9, No.3, pp. 1544-1550, 2002

Abstract Superficial bladder tumors are by far the most common form of bladder cancer managed by practicing urologists. Indeed up to 75% of initial tumors fall in this category and because of the high recurrence rate, superficial tumors represent over 90% of tumor events being treated. New diagnostic methods have been developed to improve the sensitivity of tumor detection of both cystoscopy and urinary cytology. Risk stratification of patients based on simple clinical parameters provides new opportunities for adapting monitoring strategies as well as providing a rationale for the use of intravesical chemotherapy and immunotherapy. Finally, More >